p38 mitogen-activated protein kinase-dependent regulation of SRC-3 and involvement in retinoic acid receptor alpha signaling in embryonic cortical neurons.
Appropriate retinoic acid (RA) signaling is essential in the development of the central nervous system (CNS). Previous studies have shown that RA activates p38 mitogen-activated protein kinase (MAPK) and steroid receptor coactivator (SRC)-3 in tumor cells in vitro. It is unknown whether the activation of p38 MAPK and SRC-3 is involved in RA-mediated CNS development. The current study investigated a possible role for p38 MAPK in the regulation of (SRC)-3 phosphorylation/degradation and in retinoic acid receptor (RAR)alpha signaling in mouse fetal cortical neurons treated with all-trans retinoic acid (ATRA). Results showed that ATRA treatment rapidly activated p38 MAPK, which in turn resulted in phosphorylation with subsequent degradation of SRC-3. Inhibition of p38 MAPK by SB203580 blocked the phosphorylation and degradation of SRC-3. The binding of RARalpha to retinoic acid responsive element (RARE) was rapidly increased in neurons following ATRA treatment. Inhibition of p38 MAPK significantly enhanced the RARalpha-RARE binding activity, but had no effects on ATRA-induced decrease of RARalpha. Treatment of the fetal cortical neurons with ATRA significantly increased the expression of HOXd3, a retinoid-target gene. The increase of HOXd3 expression was augmented when p38 MAPK activity was inhibited by a specific inhibitor, SB203580. Results suggest that ATRA activates the p38 MAPK signal pathway with resultant degradation of SRC-3, and that p38 MAPK is involved in the regulation of RARalpha-mediated signaling in developing neurons.
Chai
Zhi
Z
Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, China.
Yang
Lihong
L
Yu
Baofeng
B
He
Quanren
Q
Li
Wan-I
WI
Zhou
Ran
R
Zhang
Ting
T
Zheng
Xiaoying
X
Xie
Jun
J
D000818:Animals; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000196:embryology; D004268:DNA-Binding Proteins / Q000096:biosynthesis; D051548:Histone Acetyltransferases / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D055495:Neurogenesis / Q000502:physiology*; D009474:Neurons / Q000187:drug effects; D056921:Nuclear Receptor Coactivator 3; D010766:Phosphorylation; D018168:Receptors, Retinoic Acid / Q000502:physiology*; D000072482:Retinoic Acid Receptor alpha; D015398:Signal Transduction; D015534:Trans-Activators / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D004268:DNA-Binding Proteins; C484113:Hoxd3 protein, mouse; C000607072:Rara protein, mouse; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D015534:Trans-Activators; D014212:Tretinoin; D051548:Histone Acetyltransferases; C538867:Ncoa3 protein, mouse; D056921:Nuclear Receptor Coactivator 3; D048051:p38 Mitogen-Activated Protein Kinases